Protection from clinical peripheral sensory neuropathy in Alström Syndrome in contrast to early onset type2 diabetes
- Richard B. Paisey, MD (richard.paisey{at}nhs.net)1,
- Rosamund M. Paisey, RGN1,
- Mary P. Thomson, PhD1,
- Lynne Bower, BSc1,
- Pietro Maffei, MD3,
- Julian P H Shield, MD2,
- Sue Barnett, PhD2 and
- Jan D. Marshall, BA4
- 1Torbay Hospital, Torquay, UK
- 2Bristol Royal Hospital for Children, Bristol, UK
- 3Department of Medical and Surgical Science, University School of Medicine, Padua, Italy
- 4The Jackson Laboratory, Bar Harbor, ME, USA
Abstract
Objective: Alström syndrome, with type 2 diabetes, and blindness could confer a high risk of foot ulceration. Clinical testing for neuropathy in Alström syndrome and matched young onset type 2 diabetic subjects was therefore undertaken.
Research design and methods: Fifty eight subjects with Alström syndrome, aged 8-43 years (18 insulin resistant, non-diabetic and 40 diabetic) and thirty young onset diabetic subjects aged 13-35 years were studied. Neuropathy symptom questionnaires were administered. Graded monofilament and 128MHz tuning fork vibration perception were assessed in both feet.
Results: Neuropathic symptoms, loss of monofilament and/or vibration perception were reported by 12 of the 30 young type 2 diabetic subjects (six had neuropathic ulceration) but none of the subjects with Alström syndrome.
Conclusions: The striking preservation of protective foot sensation in Alström syndrome may provide a clue to the causes of differential susceptibility to neuropathy in the wider diabetic population.
Footnotes
-
- Received August 29, 2008.
- Accepted December 4, 2008.
- Copyright © American Diabetes Association











